The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2022
Filed:
Feb. 09, 2018
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université Paul Sabatier Toulouse Iii, Toulouse, FR;
Centre Hospitalier Universitaire DE Toulouse, Toulouse, FR;
Gilles Favre, Toulouse, FR;
Magdalena Pohorecka, Toulouse, FR;
INSERM (INSTITUT NATIONAL DE LA SANTéET DE LA RECHERCHE MEDICALE), Paris, FR;
UNIVERSITE PAUL SABATIER TOULOUSE III, Toulouse, FR;
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, Toulouse, FR;
Abstract
The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of 10 SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor of activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression of 15 SLITRK6 also paves the way of strategies based on depletion of the residual cancer cells by targeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drug conjugates binding to SLITRK6.